Avandia Day Two Might Be Same Old Song Even With Broken RECORD
This article was originally published in The Pink Sheet Daily
Executive Summary
There may be more at stake for FDA, and the pharmaceutical industry in general, in how the advisory committees interpret the RECORD trial than there is for Avandia itself.